These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38700250)

  • 1. Sequential administration of peripheral nerve blocks and onabotulinumtoxinA for the treatment of chronic migraine and other headache disorders-A retrospective tolerability and safety study.
    Anderson CC; Iser CR; Hirte IL; Boddu S; Girardo ME; VanderPluym JH; Starling AJ
    Headache; 2024 Jun; 64(6):663-673. PubMed ID: 38700250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine.
    Winner PK; Kabbouche M; Yonker M; Wangsadipura V; Lum A; Brin MF
    Headache; 2020 Mar; 60(3):564-575. PubMed ID: 32037549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study.
    Winner PK; Blumenfeld AM; Eross EJ; Orejudos AC; Mirjah DL; Adams AM; Brin MF
    Drug Saf; 2019 Aug; 42(8):1013-1024. PubMed ID: 31102144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine.
    Bratbak DF; Nordgård S; Stovner LJ; Linde M; Dodick DW; Aschehoug I; Folvik M; Tronvik E
    Cephalalgia; 2017 Apr; 37(4):356-364. PubMed ID: 27154997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
    Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.
    Mathew NT; Jaffri SF
    Headache; 2009; 49(10):1466-78. PubMed ID: 19912346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
    Aurora SK; Dodick DW; Diener HC; DeGryse RE; Turkel CC; Lipton RB; Silberstein SD
    Acta Neurol Scand; 2014 Jan; 129(1):61-70. PubMed ID: 24107267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
    Aurora SK; Dodick DW; Turkel CC; DeGryse RE; Silberstein SD; Lipton RB; Diener HC; Brin MF;
    Cephalalgia; 2010 Jul; 30(7):793-803. PubMed ID: 20647170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
    Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
    J Headache Pain; 2019 Feb; 20(1):12. PubMed ID: 30709333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks.
    Oterino A; Ramón C; Pascual J
    J Headache Pain; 2011 Apr; 12(2):235-8. PubMed ID: 21298315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study.
    Domínguez C; Pozo-Rosich P; Torres-Ferrús M; Hernández-Beltrán N; Jurado-Cobo C; González-Oria C; Santos S; Monzón MJ; Latorre G; Álvaro LC; Gago A; Gallego M; Medrano V; Huerta M; García-Alhama J; Belvís R; Leira Y; Leira R
    Eur J Neurol; 2018 Feb; 25(2):411-416. PubMed ID: 29171146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment.
    Vikelis M; Argyriou AA; Dermitzakis EV; Spingos KC; Makris N; Kararizou E
    J Headache Pain; 2018 Sep; 19(1):87. PubMed ID: 30225735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral Nerve Blocks for the Treatment of Headache in Older Adults: A Retrospective Study.
    Hascalovici JR; Robbins MS
    Headache; 2017 Jan; 57(1):80-86. PubMed ID: 27901275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
    Blumenfeld AM; Stark RJ; Freeman MC; Orejudos A; Manack Adams A
    J Headache Pain; 2018 Feb; 19(1):13. PubMed ID: 29404713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-Label, Multi-Dose, Pilot Safety Study of Injection of OnabotulinumtoxinA Toward the Otic Ganglion for the Treatment of Intractable Chronic Cluster Headache.
    Crespi J; Bratbak D; Dodick DW; Matharu M; Solheim O; Gulati S; Berntsen EM; Tronvik E
    Headache; 2020 Sep; 60(8):1632-1643. PubMed ID: 32583902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine.
    Diener HC; Dodick DW; Turkel CC; Demos G; Degryse RE; Earl NL; Brin MF
    Eur J Neurol; 2014 Jun; 21(6):851-9. PubMed ID: 24628923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of simultaneous administration of occipital nerve block and cervical myofascial trigger point injection (MTrPI) on headache parameters in chronic migraine patients.
    Ercan M; Ertekin A
    Ir J Med Sci; 2024 Aug; 193(4):2001-2009. PubMed ID: 38451438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OnabotulinumtoxinA for the treatment of chronic migraine.
    Rothrock JF
    Headache; 2011 Apr; 51(4):659-60. PubMed ID: 21457253
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.